Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Alder Biopharmaceuticals Inc. Stories

2013-03-20 08:27:00

Company that Discovered and Developed Clazakizumab, Previously Known as ALD518, Advances New Program into Phase 2 Study BOTHELL, Wash., March 20, 2013 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced the dosing of the first patients in a proof-of-concept Phase 2 clinical study of its antibody therapeutic candidate, ALD403, targeting calcitonin gene-related peptide (CGRP) for treatment of migraine. The double-blind, placebo-controlled, randomized study will evaluate the...

2012-08-27 02:25:01

BOTHELL, Wash., Aug. 27, 2012 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease. The milestone payment is part of the collaboration between Alder and Bristol-Myers Squibb that was formed in 2009 for the development of ALD518/BMS-945429. Under the...

2012-06-04 02:26:12

BOTHELL, Wash., June 4, 2012 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that the company is scheduled to present at the Jefferies Global Healthcare Conference at 11:30 a.m. EDT on Tuesday, June 5. Randall Schatzman, Ph.D., president and chief executive officer, will provide an overview of the company and an update about its clinical programs. "We look forward to this opportunity to provide an update about Alder as we move forward with clinical investigations of...

2012-05-07 02:32:22

BOTHELL, Wash., May 7, 2012 /PRNewswire/ -- Alder BioPharmaceuticals Inc. today announced the initiation of a Phase 1 clinical study of its antibody therapeutic candidate, ALD403, targeting the calcitonin gene-related peptide (CGRP) for treatment of migraine. The placebo-controlled, single ascending-dose study will evaluate the safety and tolerability of ALD403 administered via both intravenous infusion and subcutaneous injection. Healthy volunteers will be enrolled in...

2012-04-19 02:29:31

BOTHELL, Wash., April 19, 2012 /PRNewswire/ -- Alder BioPharmaceuticals Inc. today announced the closing of a $38 million Series D financing to support the development of the company's clinical stage pipeline. The financing was led by a new investor, Novo Ventures, and joined by existing Alder investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Peter Bisgaard, a partner with Novo Ventures, will join Alder's board of directors. Proceeds...

2012-02-24 07:00:00

BOTHELL, Wash., Feb. 24, 2012 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that Randall Schatzman, Ph.D., president and chief executive officer, will participate in a panel focused on antibody therapeutics during the RBC Capital Markets Global Healthcare Conference in New York City at 10 a.m. EST on Tuesday, February 28. "As a class antibody therapeutics have been highly successful, however there have been limitations to conventional technologies that have held the...

2011-06-20 07:00:00

BOTHELL, Wash., June 20, 2011 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6). The milestone payment is part of the Alder/Bristol-Myers Squibb collaboration that was formed in 2009 for the development of ALD518/BMS-945429. Under the...

2010-12-07 11:16:00

ORLANDO, Fla., Dec. 7, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer (NSCLC). After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients who received ALD518 experienced hemoglobin level increases from less than 11 g/dL to more than 12...

2010-11-06 11:26:00

ATLANTA, Nov. 6, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from two clinical studies of its ALD518 investigational antibody therapeutic will be presented at the Annual Meeting of the American College of Rheumatology in Atlanta. "We continue to be encouraged about the clinical data from the Phase 2a study of the IV formulation of ALD518, and, for the first time, from our Phase 1 study of the subcutaneous formulation of ALD518," said Randall Schatzman,...

2010-11-01 11:11:00

BOTHELL, Wash., Nov. 1, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that it has appointed A. Bruce Montgomery, M.D., to the company's board of directors. Dr. Montgomery, 57, served as founder and chief executive officer of Corus Pharmaceuticals from 2001 through its acquisition in 2006 by Gilead Sciences. While at Gilead, he served as Senior Vice President and Head of Respiratory Therapeutics where he successfully led the approval of Cayston (aztreonam) as a...